vTv Therapeutics
VTVT
25 hedge funds and large institutions have $4.44M invested in vTv Therapeutics in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
200% more capital invested
Capital invested by funds: $1.48M → $4.44M (+$2.96M)
39% more funds holding
Funds holding: 18 → 25 (+7)
0.08% more ownership
Funds ownership: 0.06% → 0.14% (+0.08%)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
+$2.55M |
| 2 |
Renaissance Technologies
New York
|
+$617K |
| 3 |
Two Sigma Investments
New York
|
+$437K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$166K |
| 5 |
Millennium Management
New York
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$303K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$293K |
| 3 |
D.E. Shaw & Co
New York
|
-$35K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$27K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$17.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
D.E. Shaw & Co
New York
| – | -$35K | -517 | Closed |
|
|
ECM
27
ExodusPoint Capital Management
New York
| – | -$27K | -402 | Closed |
|
|
GWM
28
Geneos Wealth Management
Englewood,
Colorado
| – | -$4K | -63 | Closed |
|
VTVT Hedge Fund Activity: Q1 2020 in Review
25 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2020, worth a combined $4.44M — up 200% from $1.48M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new VTVT positions and 3 closed out — a net gain of 8 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Frazier Management, opening a new position worth an estimated $2.55M. The largest seller was Barclays, cutting an estimated $303K.
- 25 institutional investors held vTv Therapeutics (VTVT) as of Q1 2020, up from 18 in Q4 2019.
- Funds reported $4.44M of vTv Therapeutics stock for Q1 2020, up 200% quarter-over-quarter.
- 11 funds opened new vTv Therapeutics positions in Q1 2020 and 3 closed out, a net change of +8 holders.
- The largest vTv Therapeutics buyer in Q1 2020 was Frazier Management, an estimated $2.55M added.
- The largest vTv Therapeutics seller in Q1 2020 was Barclays, an estimated $303K sold.
Based on aggregated 13F filings for Q1 2020.